While targeted and immunotherapeutic options exist for microsatellite instability, human epidermal growth factor receptor 2 (HER2)-positive, and EBV-positive GC,16 a significant subset of GSRCC patients is HER2-negative, EBV-negative, and proficient in mismatch repair (pMMR). The gene discussed is ERBB2; the disease is gastric cancer.